We are pleased to report that Filsuvez®, the gel developed by Amryt Pharma as a possible treatment to promote the healing of partial thickness wounds associated with Dystrophic and Junctional EB, has been approved by the Medical Healthcare & Products Regulatory Agency (MHRA) for use in Great Britain.

This is positive news following on from the European Medicines Agency (EMA) approval earlier in the year and is another step closer to having this treatment available through the NHS. For that to happen, the next step is for Filsuvez® to be approved by NICE, the National Institute for Health and Care Excellence, a decision is due from them in May 2023.

For more information, please read the full press release from Amryt Pharma.

Filsuvez® FAQs